Cabaletta Bio, Inc. announced promising clinical data regarding its investigational therapy, resecabtagene autoleucel (rese-cel), for autoimmune diseases during recent scientific meetings. Among the ...
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results